Literature DB >> 29472422

Prolonged paralysis with atracurium use in a patient with Rubinstein-Taybi syndrome.

T Kumaravadivel Dharmalingam1, Constance Liew Sat Lin2, Rajesh Kumar Muniandy2.   

Abstract

Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder that occurs due to a microdeletion of chromosome 16p13. The craniofacial abnormalities in these patients may pose a challenge for anaesthetist performing tracheal intubation. However, there are no known reported cases of drug interaction with non-depolarising muscle relaxant in patients with RTS. This young patient with RTS presented with an unexpected prolonged atracurium effect during the course of anaesthesia. After ruling out other possible causes, we have come to a conclusion that RTS itself could have played a role in the prolonged effect of atracurium. However, further studies will be needed to confirm this hypothesis. In the meantime, care should be used when using muscle relaxants in patients with RTS. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anaesthesia; pharmacology and therapeutics; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 29472422      PMCID: PMC5847828          DOI: 10.1136/bcr-2017-222692

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Anesthetic management of a child with Rubinstein-Taybi syndrome for cervical dermoid cyst excision.

Authors:  F Bozkirli; B Günaydin; H Celebi; D T Akçali
Journal:  J Anesth       Date:  2000       Impact factor: 2.078

2.  Anaesthesia in an adult with Rubenstein-Taybi syndrome using the ProSeal laryngeal mask airway.

Authors:  S J Twigg; T M Cook
Journal:  Br J Anaesth       Date:  2002-11       Impact factor: 9.166

3.  Anesthetic management of children with Rubinstein-Taybi syndrome--case reports.

Authors:  Shvetank Agarwal; Yasser Haidar Ahmad; Monica Talpesh; Maria Zestos
Journal:  Middle East J Anaesthesiol       Date:  2011-06

4.  Succinylcholine in Rubinstein-Taybi syndrome.

Authors:  J A Stirt
Journal:  Anesthesiology       Date:  1982-11       Impact factor: 7.892

5.  Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations.

Authors:  F Petrij; H G Dauwerse; R I Blough; R H Giles; J J van der Smagt; R Wallerstein; P D Maaswinkel-Mooy; C D van Karnebeek; G J van Ommen; A van Haeringen; J H Rubinstein; H M Saal; R C Hennekam; D J Peters; M H Breuning
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

6.  Anaesthetic Management of Children with Rubinstein-Taybi Syndrome.

Authors:  Mahmut Alp Karahan; Hüseyin Sert; Zeliha Ayhan; Bülend Ayhan
Journal:  Turk J Anaesthesiol Reanim       Date:  2016-06-01

7.  Metabolism and kinetics of atracurium: an overview.

Authors:  E A Neill; D J Chapple; C W Thompson
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

8.  Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium.

Authors:  K Leslie; D I Sessler; A R Bjorksten; A Moayeri
Journal:  Anesth Analg       Date:  1995-05       Impact factor: 5.108

9.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.

Authors:  S J Basta; H H Ali; J J Savarese; N Sunder; M Gionfriddo; G Cloutier; C Lineberry; A E Cato
Journal:  Anesth Analg       Date:  1982-09       Impact factor: 5.108

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.